Lung Cancer: Novel Therapeutic Approaches

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 5457

Special Issue Editor


E-Mail Website
Guest Editor
Division of Thoracic Surgery, Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo 190-8531, Japan
Interests: lung neoplasms; surgical therapy; immunotherapy; radiation therapy; photodynamic therapy

Special Issue Information

Dear Colleagues,

In addition to the conventional three major treatment methods of surgery, chemotherapy, and radiation therapy, the effectiveness of immunotherapy has recently been proven, and it has become one of the four major treatment methods for lung cancer. In particular, various molecular targeted drugs and angiogenesis inhibitors have been developed for chemotherapy, and in immunotherapy, not only immune checkpoint inhibitors but also cancer vaccine therapies have been developed and many clinical trials are being conducted. At the same time, many biomarkers have been discovered, and personalized treatment for each patient is beginning to prevail worldwide.

Now, in addition to these four major existing treatments, we must also pay attention to the fifth treatment. For example, photodynamic therapy and photothermal therapy have been reported to be effective in the local treatment of cancer and are attracting attention. I believe that there are other treatment methods derived from translational research that are still at the animal experiment level. In addition, new technologies may make it possible to diagnose lesions less invasively or with a higher positive diagnosis rate, leading to treatment without rate-limiting steps.

This theme invites original papers, case reports, and clinical trials, in addition to reviews of new therapies, including combinations of existing therapies. We are also looking for new diagnostic modalities directly related to treatment. In addition to the treatment of primary lung cancer, treatment methods related to tumors that occur in the chest, such as metastatic lung tumors and mediastinal tumors, are also welcome. We hope that this will lead to higher therapeutic efficacy in the treatment of lung cancer in the future.

Potential topics include, but are not limited to:

  • New surgical methods (including resection methods, approaches, and anesthesia)
  • New drug therapies (including chemotherapy, gene therapy, and immunotherapy)
  • New cell therapies (including immune cell therapy)
  • Phototherapy
  • Other new treatment methods
  • Combination of existing treatments

Dr. Tomonari Kinoshita
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung neoplasm
  • new therapy
  • combined therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 4773 KiB  
Article
Transarterial Treatment of Lung Cancer
by Atsushi Hori, Ikuo Dejima, Shinichi Hori, Shuto Oka, Tatsuya Nakamura and Shota Ueda
Life 2022, 12(7), 1078; https://doi.org/10.3390/life12071078 - 19 Jul 2022
Viewed by 1927
Abstract
Purpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from [...] Read more.
Purpose: The treatment efficacy of the transarterial approach to lung cancer is evaluated. Materials and Methods: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated. Result: The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study. Conclusion: The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases. Full article
(This article belongs to the Special Issue Lung Cancer: Novel Therapeutic Approaches)
Show Figures

Figure 1

10 pages, 750 KiB  
Article
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
by Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo and Jae Myoung Noh
Life 2022, 12(2), 292; https://doi.org/10.3390/life12020292 - 16 Feb 2022
Cited by 3 | Viewed by 2601
Abstract
This study evaluated the toxicity associated with radiation techniques on curative re-irradiation (re-RT) in patients with thoracic recurrence of non-small cell lung cancer (NSCLC). From 2011 to 2019, we retrospectively reviewed the data of 63 patients with salvage re-RT for in-field or marginal [...] Read more.
This study evaluated the toxicity associated with radiation techniques on curative re-irradiation (re-RT) in patients with thoracic recurrence of non-small cell lung cancer (NSCLC). From 2011 to 2019, we retrospectively reviewed the data of 63 patients with salvage re-RT for in-field or marginal recurrence of NSCLC at two independent institutions. Re-RT techniques using X-ray beams and proton beam therapy (PBT) were also included. Re-RT had a 2-year overall survival (OS) and local progression-free survival of 48.0% and 52.0%, respectively. Fifteen patients experienced grade 3 or higher toxicity after re-RT. The complication rates were 18.2% (4/22) and 26.8% (11/41) in PBT patients and X-ray patients, respectively. Airway or esophageal fistulas occurred in seven patients (11.1%). Fistulas or severe airway obstruction occurred in patients with tumors adjacent to the proximal bronchial tree and esophagus, who underwent hypofractionated radiotherapy (RT) or concurrent chemotherapy, and with a higher dose exposure to the esophagus. In conclusion, salvage re-RT was feasible even in patients with local recurrence within the previous RT field. PBT showed similar survival outcomes and toxicity to those of other techniques. However, thoracic re-RT should be performed carefully considering tumor location and RT regimens such as the fraction size and concurrent chemotherapy. Full article
(This article belongs to the Special Issue Lung Cancer: Novel Therapeutic Approaches)
Show Figures

Figure 1

Back to TopTop